Skip to content

The effect of vitamin D3 in the treatment of diabetes

The effect of vitaminD3 supplementation on glucose and lipid profile, blood pressure, liver and kidney indices in overweight and obese (grade 1) patients with type2 diabetes

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201605112365N12
Enrollment
90
Registered
2016-08-12
Start date
2016-07-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus type2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Pearl of vitaminD 50000IU weekly for 8 weeks. Intervention 2: Placebo of edible paraffin and similar to vitaminD3.
Prevention
Placebo
Pearl of vitaminD 50000IU weekly for 8 weeks

Sponsors

Vice Chancellor for research of Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diabetes type2 in both sexes; 25 to 65 years; Serum 25 hydroxy vitaminD3 levels less than 30 nano grams per milliliter (ng/ml); Body mass index (BMI) between 25 to 35 kilograms per square meter (kg/m²); glycated hemoglobin (HbA1c) level less than 8.5%; Willingness to participate in the project Exclusion criteria: Insulin consumption; Smoking or drinking alcohol at least once a week; Regular consumption of (at least once a week) herbal, antioxidant, multivitamin mineral, vitaminD3 and omega3 supplements; Taking birth control pills and Nonsteroidal antiiflammatory drugs (NSAIDs) in the last three months; Pregnancy and lactatin; Diagnosed diseases such as cancer, digestive diseases, liver and kidney diseases, autoimmune diseases, inflammation, hypothyroidism, polycystic ovarian syndrome; Changing usual and balanced diet with vegetarian diets or single product or any other unusual changes in the last three months; triglyceride levels more than 250 Milligrams per deciliter (mg/dl) and cholesterol more than 300 mg/dl; Exposure to sun and use of solarium for tanning up to 3 months before the start of the study; Taking medications affecting vitaminD3 metabolism such as Antiepileptic drugs and corticosteroids; Consuming less than 90% of supplements; Suffering from any acute illness; Any change in the type and amount of blood glucose lowering drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
HbA1c. Timepoint: Before and 8 weeks after intervention. Method of measurement: Laboratory kit.;Fasting blood sugar. Timepoint: Before and 8 weeks after intervention. Method of measurement: Laboratory kit.;Lipid profile. Timepoint: Before and 8 weeks after intervention. Method of measurement: Laboratory kit.;Blood pressur. Timepoint: Before and 8 weeks after intervention. Method of measurement: Barometer.;Liver indices. Timepoint: Before and 8 weeks after intervention. Method of measurement: Laboratory kit.;Kidney indices. Timepoint: Before and 8 weeks after intervention. Method of measurement: Laboratory kit.

Secondary

MeasureTime frame
Serum 25(OH)D3 Level. Timepoint: Before and 8 weeks after intervention. Method of measurement: Laboratory Kit.;Fasting Insulin. Timepoint: Before and 8 weeks after intervention. Method of measurement: laboratory Kit.;Insulin resistance. Timepoint: Before and 8 weeks after intervention. Method of measurement: HOMA-IR formula.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Vafa

Iran University of Medical Sciences

Rezavafa@yahoo.com; Rezavafa@iums.ac.ir+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026